Video summary

Von Willebrand disease

Main summary

Key takeaways

Educational

Main ideas, concepts, and lessons

  • What von Willebrand disease (vWD) is

    • Named after Finnish doctor Erik Adolf von Willebrand, who first described the condition.
    • A bleeding disorder caused by:
      • Low amount of von Willebrand factor (vWF), and/or
      • Poor/abnormal quality of vWF.
    • vWF is essential for primary hemostasis (platelet adhesion/aggregation) and for carrying/stabilizing factor VIII.

  • How normal clotting is supposed to work (hemostasis overview)

    • Primary hemostasis (platelet plug formation)

      • Injury exposes collagen in the vessel wall.
      • Local endothelial cells release more vWF.
      • vWF acts like “glue”:
        • It binds to the damaged area and provides a binding surface for platelets.
      • Platelets bind vWF via GPIIb/IIIa (glycoprotein 2b receptors) and become activated:
        • They change shape, extend “tentacles,” and help recruit more platelets.
      • Activated platelets release mediators:
        • Serotonin and calcium
        • ADP and thromboxane A2
        • These activate additional platelets that haven’t bound vWF yet.
        • They also promote platelet expression of GPIIb/IIIa, enabling tighter aggregation.
      • Platelets catch fibrinogen, which bridges platelets (“handcuffs” concept) → plug forms.
      • The platelet plug then triggers secondary hemostasis.

    • Secondary hemostasis (fibrin clot stabilization)

      • Builds a stable fibrin mesh using coagulation pathways:
        • Extrinsic + intrinsic pathways converge into the common pathway.
      • Extrinsic pathway
        • Vessel injury exposes factor 3 (tissue factor) → activates factor 7.
        • Activated tissue factor + factor 7 + calcium → activates factor 10.
        • Factor 10 + factor 5 + calcium → forms prothrombinase complex.
        • Converts factor 2 (prothrombin) → factor 2a (thrombin).
        • Thrombin converts factor 1 (fibrinogen) → factor 1a (fibrin).
        • Thrombin activates factor 13, which uses calcium to create fibrin cross-links (stabilization).
      • Intrinsic pathway
        • Collagen activates factor 12 (Hageman factor).
        • Factor 12 → activates factor 11.
        • Factor 11 + calcium → activates factor 9.
        • Factor 8 circulates bound to vWF, which protects factor VIII from breakdown by proteins C and S.
        • During secondary hemostasis, thrombin releases factor VIII from vWF and activates it.
        • Activated factor VIII + factor IX + calcium → activates factor X → common pathway.

  • Why vWD causes bleeding

    • vWD means not enough functional vWF, leading to:
      • Failed platelet adhesion at the injury site.
      • Insufficient protection/transport of factor VIII, lowering effective factor VIII activity.
    • Net effect: the body struggles to stop bleeding.

Types of von Willebrand disease (detailed)

Inherited vWD (most cases)

vWD is subdivided into three main types (with type 2 containing subtypes):

Type 1

  • Autosomal dominant
  • Partial quantitative defect
  • Mutation in one allele → insufficient production → lower circulating vWF levels.

Type 2 (qualitative defect)

  • More complex; includes subtypes:
    • 2A, 2B, 2M: autosomal dominant
    • 2N: autosomal recessive
  • Overall: vWF amount is often present, but it doesn’t function properly.

Subtype-specific functional problems

  • Type 2A and 2M

    • vWF binds well to:
      • Subendothelial collagen
      • Factor VIII
    • But vWF cannot bind platelets
    • Analogy: “expired glue” that can’t stick platelets properly.

  • Type 2B

    • vWF is too sticky
    • Causes platelets to clump in the bloodstream even without injury.

  • Type 2N

    • vWF binds well to:
      • Subendothelial collagen
      • Platelets
    • But binds poorly to factor VIII
    • Factor VIII becomes unprotected and is broken down by proteins C and S
    • → low factor VIII levels

Type 3

  • Autosomal recessive
  • Severe quantitative deficiency
  • Extremely low vWF → impaired platelet aggregation + severely low factor VIII.

Acquired von Willebrand disease

  • Occurs when an underlying condition interferes with vWF function.
  • Example:
    • Autoimmune disorders such as systemic lupus erythematosus
      • Autoantibodies target vWF → destruction of vWF.

Clinical manifestations (by type)

  • Type 1, 2A, 2B, 2M

    • Can be:
      • Asymptomatic, or
      • Cause mild mucocutaneous bleeding
    • Examples:
      • gum bleeding
      • easy bruising
      • excessive bleeding from wounds
      • heavy menstruation
    • Often discovered only after surgery or dental work reveals bleeding tendency.
    • Can worsen with drugs that impair clotting:
      • anticoagulants
      • antiplatelet medications

  • Type 2N and Type 3

    • Severe bleeding
    • Includes:
      • joint and muscle bleeds
      • gastrointestinal hemorrhage

  • Acquired vWD

    • New bleeding symptoms appear alongside the underlying condition (e.g., autoimmune disease).

Diagnosis (laboratory approach)

Key lab patterns mentioned

  • Complete blood count (CBC)

    • Usually normal platelet count.
    • Type 2B:
      • sticky vWF causes platelet clumping
      • → thrombocytopenia

  • Coagulation profile

    • PT (prothrombin time)
      • assesses extrinsic and common pathways
      • usually normal in vWD (extrinsic pathway unaffected)
    • APTT (activated partial thromboplastin time)
      • assesses intrinsic and common pathways
      • can be normal or prolonged depending on vWF/factor VIII protection
        • Type 1:
          • APTT normal (partial quantitative deficiency; enough protection)
        • Types 2 and 3:
          • APTT prolonged
          • because compromised protection allows proteins C and S to break down factor VIII → lower factor VIII → prolonged APTT
    • TT (thrombin time)
      • measures time for fibrinogen → fibrin conversion with thrombin
      • typically normal in vWD (no impairment described for fibrinogen-to-fibrin conversion)

Specific vWD tests described (step-by-step logic)

  • vWF antigen assay

    • Measures amount of vWF in blood.
    • Low levels suggest vWD.

  • Ristocetin cofactor activity test

    • Principle:
      • Add ristocetin to a blood sample containing vWF.
      • In normal conditions, ristocetin activates vWF so platelets clump, producing visible coagulation.
    • Interpretation:
      • No clumping → reduced vWF activity → suggests vWD.

  • Factor VIII activity

    • Measures how well factor VIII works.
    • Often decreased because vWF fails to protect it from breakdown by proteins C and S.

Treatment/management (by type)

  • Types 1 and 2

    • First-choice: desmopressin (DDAVP)
    • Mechanism described:
      • Stimulates endothelial cells and megakaryocytes to release stored vWF
      • → increases circulating vWF
      • → improves clotting/bleeding control
    • Important caution:
      • Avoid desmopressin in Type 2B
        • because vWF is already overly sticky
        • boosting it can cause platelet clumping
        • → worsening thrombocytopenia
        • → potentially worse bleeding

  • Type 3

    • Treatment:
      • IV infusion of vWF concentrate
      • Often combined with factor VIII

Quick recap (core takeaways)

  • vWD involves insufficient functional vWF, which causes:
    1. Failure of platelet adhesion to injury sites
    2. Failure to carry/protect factor VIII
  • Inherited vWD:
    • Type 1: reduced vWF levels
    • Type 2: dysfunctional vWF (qualitative defect; subtypes 2A/2B/2M/2N)
    • Type 3: severe vWF deficiency
  • Acquired vWD can occur with autoimmune disease (e.g., systemic lupus erythematosus).

Speakers / sources featured

  • Erik Adolf von Willebrand (historical source referenced as the condition’s namesake)
  • Osmosis (promotional message shown in subtitles; no named speaker provided)
  • Systemic lupus erythematosus (mentioned as an example cause; not a speaker)
  • Proteins C and S (biological factors mentioned; not speakers)

Original video